Table 1 The clinical characteristics of 15 cases diagnosed with B-cell lymphoma
Patient No | Age (yrs) | Gender | Disease | WBC (× 109/L) | HGB (g/L) | PLT (× 109/L) | Lymphocyte count (× 109/L) | Monocyte count (× 109/L) | LDH (U/L) | Histological grade |
|---|---|---|---|---|---|---|---|---|---|---|
1 | 58 | M | DLBCL | 7.41 | 132 | 210 | 1.17 | 0.77 | 250 | BCL-2(+), BCL-6(−), CD10(−), CD19(+), CD20(+), Ki-67(70%) |
2 | 69 | F | DLBCL | 6.55 | 109 | 273 | 0.84 | 1.09 | 827 | BCL-2(+), BCL-6(−), CD10(−), CD19(+), CD20(+), Ki-67(90%) |
3 | 39 | F | DLBCL | 7.37 | 146 | 240 | 2.11 | 0.41 | 242 | BCL-2(−), BCL-6(+), CD10(−), CD19(−), CD20(+), Ki-67(90%) |
4 | 55 | F | MZL (B-cell) | 5.53 | 143 | 334 | 1.88 | 0.43 | 206 | BCL-2(−), BCL-6(−), CD10(−), CD19(+), CD20(−) |
5 | 60 | M | DLBCL | 4.11 | 148 | 261 | 0.97 | 0.6 | 309 | BCL-2(+), BCL-6(+), CD10(+), CD19(−), CD20(+), Ki-67(85%) |
6 | 65 | M | DLBCL | 5.96 | 143 | 134 | 1.37 | 0.5 | 162 | BCL-2(+), BCL-6(+), CD10(−), CD19(+), CD20(+), Ki-67(50%) |
7 | 58 | M | t-FL | 8.59 | 123 | 612 | 2.68 | 1.17 | 355 | BCL-2(+), BCL-6(+), CD10(−), CD19(−), CD20(+), Ki-67(60%) |
8 | 61 | M | FL | 5.67 | 137 | 199 | 1.31 | 0.35 | 216 | BCL-2(−), BCL-6(+), CD10(+), CD19(−), CD20(+), Ki-67(20%) |
9 | 62 | M | DLBCL | 4.27 | 132 | 234 | 0.65 | 0.5 | 195 | BCL-2(+), BCL-6(−), CD10(+), CD19(−), CD20(+), Ki-67(+) |
10 | 68 | M | NHL (B-cell) | 6.71 | 128 | 153 | 1.23 | 0.67 | 226 | BCL-2(−), BCL-6(+), CD10(−), CD19(−), CD20(+), Ki-67(85%) |
11 | 77 | F | NHL (B-cell) | 6.39 | 136 | 320 | 1.65 | 0.4 | 294 | BCL-2(+), BCL-6(+), CD10(−), CD20(+), Ki-67(80%) |
12 | 59 | M | DLBCL | 7.42 | 115 | 159 | 1.06 | 1.12 | 315 | BCL-2(+), BCL-6(+), CD10(−), CD20(+), Ki-67(20%) |
13 | 73 | F | FL | 1.12 | 64 | 10 | 0.52 | 0.23 | 436 | BCL-2(+), BCL-6(+), CD10(+), CD19(+), CD20(+),Ki-67(80%),c-MYC(30%), P53(60%) |
14 | 50 | F | HGBL | 3.67 | 118 | 224 | 0.79 | 0.31 | 243 | BCL-2(+), BCL-6(+), CD10(+), CD19(−), CD20(+), Ki-67(90%) |
15 | 49 | F | MCL | 5.95 | 96 | 169 | 1.21 | 0.58 | 194 | BCL-2(+), BCL-6(+), CD10(−), CD19(−), CD20(+), Ki-67(60%) |